Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Therapeutic Area Revenue Growth at Constant Currencies by Quarter
Therapeutic Area Revenue Growth at Constant Currencies (% cc) (%)
Novartis Therapeutic Area Revenue Growth at Constant Currencies: -22.0% in Q3 2026, down 26.0 pts from a year earlier.
Latest, Q3 2026
-22.0%
Period ended Sep 30, 2026
Change on a year earlier
-26.0 pts
4.0% in Q3 2025
History
12 quarters
Since Q4 2023
Sources
12
Documents cited below
Where the Q3 2026 figure comes from
“|| Total cardiovascular, renal and metabolic | 1 702 | 2 185 | – 22 | – 22”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K & Form 20-F.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Therapeutic Area Revenue Growth at Constant Currencies (% cc) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | -22.0% | -26.0 pts | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2026 | Jun 30, 2026 | -37.0% | -63.0 pts | Novartis Form 6-K (0001114448-26-000012) ↗ |
| Q1 2026 | Mar 31, 2026 | -33.0% | -59.0 pts | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q4 2025 | Dec 31, 2025 | -36.0% | -74.0 pts | Novartis Form 6-K (0001114448-26-000007) ↗ |
| Q3 2025 | Sep 30, 2025 | 4.0% | -27.0 pts | Novartis Form 6-K (0001114448-25-000003) ↗ |
| Q2 2025 | Jun 30, 2025 | 26.0% | -7.0 pts | Novartis Form 6-K (0001370368-25-000012) ↗ |
| Q1 2025 | Mar 31, 2025 | 26.0% | -15.0 pts | Novartis Form 6-K (0001370368-25-000010) ↗ |
| Q4 2024 | Dec 31, 2024 | 38.0% | +6.0 pts | Novartis Form 6-K (0001370368-25-000007) ↗ |
| Q3 2024 | Sep 30, 2024 | 31.0% | – | Novartis Form 6-K (0001370368-24-000022) ↗ |
| Q2 2024 | Jun 30, 2024 | 33.0% | – | Novartis Form 6-K (0001370368-24-000019) ↗ |
| Q1 2024 | Mar 31, 2024 | 41.0% | – | Novartis Form 6-K (0001370368-24-000017) ↗ |
| Q4 2023 | Dec 31, 2023 | 32.0% | – | Novartis Form 6-K (0001370368-24-000007) ↗ |
Cite this data
StockData. (2026). Novartis Therapeutic Area Revenue Growth at Constant Currencies (%), quarterly Q4 2023–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/ta-crm-yoy-cc-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.